Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders
Recruiting · NCT06333652 · Interventional (participants receive a specific treatment) · Lead sponsor: Mayo Clinic
View the official record on ClinicalTrials.gov →Interventions studied
Ravulizumab
What this trial is about
The researchers are testing a medication named ravulizumab for the treatment of severe preeclampsia and Hemolysis, Elevated Liver enzymes, Low Platelets (HELLP) syndrome.
Who can take part
Age range
18 Years to 50 Years
Sex
Female
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Individuals with \< 34 0/7 weeks of gestation.
- Individuals with severe preeclampsia or HELLP features.
Exclusion criteria
- Pregnant female patients presenting with disseminated intravascular coagulopathy (DIC).
- Individuals with non-reassuring fetal status requiring delivery, non-viable fetuses, previable pregnancy (\<23 0/7 weeks gestation), stroke, in utero fetal demise, known atypical hemolytic uremic syndrome, familial or acquired thrombocytopenia purpura, paroxysmal nocturnal hemoglobinuria, allergy to Ravulizumab, inability or unwillingness to sign informed consent.
Where it is running
1 location listed across 1 US state.
- Mayo Clinic Minnesota - Rochester, Minnesota, United States